infuse Life Science, Inc., a pioneering research-driven startup focused on revolutionizing the life sciences for the Ob-GYN healthcare industry, today announced that it has been selected as a finalist of the Tokyo SME grant. This grant will support the development of the company's second product, which follows its previously Tokyo SME grant-selected diagnostic method.

The selection is an important step to the company's commitment to innovation and its strong track record in research and development. This latest product, combined with our existing diagnostic solution, will enable us to offer a comprehensive suite of products to address unmet needs in the life sciences field.

“This notification of grant approval is a testament to the broader understanding of our vision beyond a single product, but as a comprehensive solution,” said Dai Saito, CEO of infuse Life Science, Inc. “We are committed to working diligently to bring these products to clinical implementation as soon as possible.”

We are pleased to announce that we have officially become a corporation and are embarking on a new chapter of growth. Concurrently, we are thrilled to welcome Dr. Yukio Suzuki as our new Chief Medical Officer and Co-Founder.

As a corporation, we will be able to accelerate our business initiatives and pursue our vision to provide innovative breakthrough methods in Ob-Gyn medical solutions. By focusing on developping technology in women's health, we aim to achieve continuous growth of the business and drive sustainable world population issues.

Under Dr. Suzuki's leadership in our medical affiars, we will expedite the Ob-Gyn medical products R&D and clinical evaluation to strengthen and expand our business pipeline.

We are committed to providing innovative solutions to address the critical issue of women's health. We appreciate your continued support.

Tokyo metropolitan SME support center advised on October 20, 2024 that one of our applications for a groundbreaking medical device development grants for women's health has advanced to the final round. This grant will enable us to maximize design possibilities and improve the lives of women worldwide.

We periodically update our blogs to keep connecting the world to infuse LS.

Under the circumstance of limitation which allows us to disclose R&D status in this beginning of the business phase, we love to have your attention and interests to our challenge for innovation.

Please drop by and check our blogs.

Our headquarters is located in Akishima City, Tokyo, at the Incubation Office TAMA, supported by the Tokyo Metropolitan SME Support Center. We are currently operating as a private LLC and plan to incorporate in December.

This is just the beginning of our life. We'll be sharing more details about our business and R&D initiatives soon.

Thank you for your continued interest and support.

CEO Dai Saito

令和6年10月1日、東京都中小企業振興公社様のご支援のもと、インフューズライフサイエンスを無事に創業いたしました。

インフューズは、産婦人科領域、Women's Healthにおいて、従来の日本固有のクラシカルな技術にAIを融合させた世界初の革新的な製品開発を進めています。 スタートアップならではの機動性を活かし、一日も早く臨床現場へ製品を届けることを目標に、事業を推進してまいります。

これまで解明が難しかった領域に新たな選択肢を提供するため、東京都多摩を起点として、アメリカをはじめとする世界へ積極的に展開してまいります。 日々革新に挑戦し、さらなる発展を目指してまいりますので、今後とも温かいご支援を賜りますようお願い申し上げます。

代表 齋藤大介